Deep Dives into Peptide Science
Research breakdowns, protocol design, and the latest findings from the world of peptide science. Written for researchers who care about the evidence.
GLP-1 Drugs, Anxiety, and Depression: What the New Data Actually Says
A large real-world study just compared semaglutide and tirzepatide to older weight-loss drugs on mental health outcomes. The results split in an unexpected direction.
Amylin Therapies: The Next Generation of Weight-Loss Drugs Beyond GLP-1s
New clinical data from ADA 2026 and ECO 2026 shows amylin-based therapies delivering double-digit weight loss with better muscle preservation and fewer GI side effects than GLP-1s alone. Here's why every major pharma company is building an amylin program.
Survodutide Cuts Liver Fat by 63% and Visceral Fat by 34% — Why the Weight Loss Numbers Tell Only Half the Story
The SYNCHRONIZE-1 trial showed survodutide delivers 16.6% weight loss, but the real story is what happens to the fat you can't see — deep visceral and liver fat that drives cardiometabolic disease.
FDA Scientists vs. RFK Jr.: The Evidence Battle That Could Decide Peptide Access
FDA career scientists say there's insufficient evidence for all 7 peptides under review, directly contradicting RFK Jr.'s push to expand access. Here's what the briefing documents actually say.
The Hidden Impurity in Compounded Tirzepatide: What Lilly's Lab Found in Your B12 Combo
Eli Lilly's analytical labs discovered a novel chemical impurity in compounded tirzepatide-B12 products—a compound formed by a reaction between the two ingredients that nobody has tested for safety.
VK2735: The Oral Weight Loss Pill That Lost 26 Pounds in 13 Weeks
Viking Therapeutics just showed that their oral dual GLP-1/GIP agonist VK2735 produced 12.2% weight loss in 13 weeks — no injections required. Here's what the Phase 2 data means for the future of weight loss pills.
Survodutide Shrinks Liver Fat by 84% in Phase 3 Trial — A New Era for Fatty Liver Disease
A landmark Nature Medicine trial shows survodutide dramatically reduces liver fat and body weight in patients with fatty liver disease. Here's what the data actually says.
Why BPC-157 Still Hasn't Reached Clinical Trials After 30 Years of Research
BPC-157 has thousands of preclinical studies showing tissue-healing effects across nearly every organ system. So why does it still have zero completed clinical trials? A May 2026 review finally explains the gap.
Do GLP-1 Drugs Sabotage Fat Grafts? What the Latest Surgery Data Actually Shows
New studies show semaglutide users face a 45% complication rate in cosmetic surgery. Here's why GLP-1 drugs interfere with fat graft biology and what surgeons are doing about it.
Thymosin Alpha-1 in Cancer Immunotherapy: New Mechanism Restores Immunity After Chemo
Three 2026 studies reveal how thymosin alpha-1 restores antitumor immunity after chemotherapy, reverses T-cell exhaustion, and synergizes with checkpoint inhibitors.
Semaglutide Cuts Cardiovascular Events by 25% in Rheumatoid Arthritis Patients: New Study
A June 2026 study found semaglutide reduced major cardiovascular events by 25% and heart failure by 31% in obese adults with type 2 diabetes and rheumatoid arthritis, with a surprising bonus: fewer patients needed stronger RA medications.